Do analysts recommend ENSC or LPCN?

Lipocine has a consensus price target of $15.00, indicating a potential upside of 565.19%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33

Do analysts recommend QNCX or ENSC?

Quince Therapeutics presently has a consensus price target of $65.00, suggesting a potential upside of 5,890.78%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Quince Therapeutics 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate ENSC or XCUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Exicure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ENSC or XCUR more profitable?

Exicure has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Exicure's return on equity of -148.87% beat Ensysce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Ensysce Biosciences -250.39% -766.45% -256.59% Exicure N/A -148.87% -61.09%

Do analysts recommend ENSC or KTTA?

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 333.53%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts recommend ENSC or QCLS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mymd Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Ensysce Biosciences (ENSC) Competitors

$0.27 -0.01 (-2.14%)

As of 01:24 PM Eastern

Compare

ENSC vs. LPCN, QNCX, XCUR, KTTA, and QCLS

Should you buy Ensysce Biosciences stock or one of its competitors? MarketBeat compares Ensysce Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ensysce Biosciences include Lipocine (LPCN), Quince Therapeutics (QNCX), Exicure (XCUR), Pasithea Therapeutics (KTTA), and Mymd Pharmaceuticals (QCLS). These companies are all part of the "pharmaceutical products" industry.

How does Ensysce Biosciences compare to Lipocine?

Ensysce Biosciences (NASDAQ:ENSC) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

Lipocine has lower revenue, but higher earnings than Ensysce Biosciences. Lipocine is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.79	-$10.18M	-$3.35	N/A
Lipocine	$1.98M	9.38	-$9.63M	-$1.88	N/A

Ensysce Biosciences has a net margin of -250.39% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Lipocine	-571.18%	-66.70%	-59.39%

Lipocine has a consensus price target of $15.00, indicating a potential upside of 565.19%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by insiders. Comparatively, 6.4% of Lipocine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Lipocine had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Ensysce Biosciences. Lipocine's average media sentiment score of 0.51 beat Ensysce Biosciences' score of 0.29 indicating that Lipocine is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Lipocine	Positive

Ensysce Biosciences has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.48, suggesting that its share price is 52% less volatile than the broader market.

Summary

Lipocine beats Ensysce Biosciences on 12 of the 16 factors compared between the two stocks.

How does Ensysce Biosciences compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership, media sentiment and dividends.

Quince Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market.

Ensysce Biosciences has higher revenue and earnings than Quince Therapeutics. Quince Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
Ensysce Biosciences	$5.07M	0.79	-$10.18M	-$3.35	N/A

Quince Therapeutics presently has a consensus price target of $65.00, suggesting a potential upside of 5,890.78%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quince Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Quince Therapeutics' return on equity of -372.88% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
Ensysce Biosciences	-250.39%	-766.45%	-256.59%

In the previous week, Quince Therapeutics and Quince Therapeutics both had 2 articles in the media. Quince Therapeutics' average media sentiment score of 1.89 beat Ensysce Biosciences' score of 0.29 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Quince Therapeutics	Very Positive
Ensysce Biosciences	Neutral

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Quince Therapeutics beats Ensysce Biosciences on 9 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to Exicure?

Ensysce Biosciences (NASDAQ:ENSC) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Ensysce Biosciences has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Exicure has a beta of 3.53, indicating that its stock price is 253% more volatile than the broader market.

Exicure has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Exicure's return on equity of -148.87% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Exicure	N/A	-148.87%	-61.09%

In the previous week, Exicure had 4 more articles in the media than Ensysce Biosciences. MarketBeat recorded 6 mentions for Exicure and 2 mentions for Ensysce Biosciences. Exicure's average media sentiment score of 1.64 beat Ensysce Biosciences' score of 0.29 indicating that Exicure is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Exicure	Very Positive

5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 2.8% of Ensysce Biosciences shares are held by company insiders. Comparatively, 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Exicure has lower revenue, but higher earnings than Ensysce Biosciences. Exicure is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.79	-$10.18M	-$3.35	N/A
Exicure	$500K	43.24	-$4.95M	-$1.55	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Exicure beats Ensysce Biosciences on 11 of the 13 factors compared between the two stocks.

How does Ensysce Biosciences compare to Pasithea Therapeutics?

Ensysce Biosciences (NASDAQ:ENSC) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 333.53%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Ensysce Biosciences has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Ensysce Biosciences has higher revenue and earnings than Pasithea Therapeutics. Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.79	-$10.18M	-$3.35	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$2.08	N/A

Pasithea Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Pasithea Therapeutics' return on equity of -57.44% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Pasithea Therapeutics	N/A	-57.44%	-53.61%

In the previous week, Pasithea Therapeutics had 1 more articles in the media than Ensysce Biosciences. MarketBeat recorded 3 mentions for Pasithea Therapeutics and 2 mentions for Ensysce Biosciences. Pasithea Therapeutics' average media sentiment score of 0.62 beat Ensysce Biosciences' score of 0.29 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Pasithea Therapeutics	Positive

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Pasithea Therapeutics beats Ensysce Biosciences on 10 of the 15 factors compared between the two stocks.

How does Ensysce Biosciences compare to Mymd Pharmaceuticals?

Ensysce Biosciences (NASDAQ:ENSC) and Mymd Pharmaceuticals (NASDAQ:QCLS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

Ensysce Biosciences has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Mymd Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market.

Ensysce Biosciences has higher revenue and earnings than Mymd Pharmaceuticals. Mymd Pharmaceuticals is trading at a lower price-to-earnings ratio than Ensysce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ensysce Biosciences	$5.07M	0.79	-$10.18M	-$3.35	N/A
Mymd Pharmaceuticals	N/A	N/A	-$11.63M	-$20.69	N/A

In the previous week, Ensysce Biosciences had 1 more articles in the media than Mymd Pharmaceuticals. MarketBeat recorded 2 mentions for Ensysce Biosciences and 1 mentions for Mymd Pharmaceuticals. Mymd Pharmaceuticals' average media sentiment score of 1.89 beat Ensysce Biosciences' score of 0.29 indicating that Mymd Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Ensysce Biosciences	Neutral
Mymd Pharmaceuticals	Very Positive

Mymd Pharmaceuticals has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -250.39%. Mymd Pharmaceuticals' return on equity of -76.40% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ensysce Biosciences	-250.39%	-766.45%	-256.59%
Mymd Pharmaceuticals	N/A	-76.40%	-35.10%

5.6% of Ensysce Biosciences shares are owned by institutional investors. Comparatively, 9.6% of Mymd Pharmaceuticals shares are owned by institutional investors. 2.8% of Ensysce Biosciences shares are owned by insiders. Comparatively, 0.9% of Mymd Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mymd Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Ensysce Biosciences and Mymd Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Ensysce Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENSC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENSC vs. The Competition

Export

Metric	Ensysce Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.13M	$3.37B	$6.39B	$12.60B
Dividend Yield	N/A	2.29%	2.69%	5.30%
P/E Ratio	-0.08	18.01	21.14	26.64
Price / Sales	0.79	182.95	513.05	95.52
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	0.43	6.53	9.81	6.79
Net Income	-$10.18M	$24.15M	$3.56B	$337.23M
7 Day Performance	-10.89%	-1.39%	0.40%	2.67%
1 Month Performance	-29.56%	1.04%	4.87%	6.66%
1 Year Performance	-87.66%	51.35%	31.14%	37.99%

Ensysce Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENSC Ensysce Biosciences	0.5621 of 5 stars	$0.27 -2.1%	N/A	-87.2%	$4.13M	$5.07M	N/A	10
LPCN Lipocine	4.1319 of 5 stars	$2.26 flat	$15.00 +563.7%	-32.1%	$18.63M	$1.98M	N/A	10	Short Interest Decrease
QNCX Quince Therapeutics	2.1585 of 5 stars	$1.20 +9.1%	$65.00 +5,316.7%	-89.2%	$17.93M	N/A	N/A	60	News Coverage Positive News Gap Up
XCUR Exicure	1.2376 of 5 stars	$2.67 -5.0%	N/A	-65.9%	$17.91M	$500K	N/A	50	News Coverage Earnings Report Short Interest Decrease
KTTA Pasithea Therapeutics	2.497 of 5 stars	$0.68 -2.8%	$3.00 +341.1%	-26.3%	$17.45M	N/A	N/A	3	News Coverage Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENSC) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ensysce Biosciences (ENSC) Competitors

ENSC vs. LPCN, QNCX, XCUR, KTTA, and QCLS

How does Ensysce Biosciences compare to Lipocine?

Summary

How does Ensysce Biosciences compare to Quince Therapeutics?

Summary

How does Ensysce Biosciences compare to Exicure?

Summary

How does Ensysce Biosciences compare to Pasithea Therapeutics?

Summary

How does Ensysce Biosciences compare to Mymd Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ensysce Biosciences (ENSC) Competitors

ENSC vs. LPCN, QNCX, XCUR, KTTA, and QCLS

How does Ensysce Biosciences compare to Lipocine?

Which has preferable earnings & valuation, ENSC or LPCN?

Is ENSC or LPCN more profitable?

Do analysts recommend ENSC or LPCN?

Do institutionals and insiders have more ownership in ENSC or LPCN?

Does the media refer more to ENSC or LPCN?

Which has more risk and volatility, ENSC or LPCN?

Summary

How does Ensysce Biosciences compare to Quince Therapeutics?

Which has more risk & volatility, QNCX or ENSC?

Which has preferable valuation and earnings, QNCX or ENSC?

Do analysts recommend QNCX or ENSC?

Is QNCX or ENSC more profitable?

Does the media favor QNCX or ENSC?

Do institutionals & insiders hold more shares of QNCX or ENSC?

Summary

How does Ensysce Biosciences compare to Exicure?

Which has more volatility and risk, ENSC or XCUR?

Is ENSC or XCUR more profitable?

Does the media refer more to ENSC or XCUR?

Do institutionals and insiders have more ownership in ENSC or XCUR?

Which has preferable valuation and earnings, ENSC or XCUR?

Do analysts rate ENSC or XCUR?

Summary

How does Ensysce Biosciences compare to Pasithea Therapeutics?

Do analysts recommend ENSC or KTTA?

Which has more risk and volatility, ENSC or KTTA?

Which has higher earnings & valuation, ENSC or KTTA?

Is ENSC or KTTA more profitable?

Does the media prefer ENSC or KTTA?

Do insiders & institutionals hold more shares of ENSC or KTTA?

Summary

How does Ensysce Biosciences compare to Mymd Pharmaceuticals?

Which has more volatility & risk, ENSC or QCLS?

Which has higher valuation and earnings, ENSC or QCLS?

Does the media refer more to ENSC or QCLS?

Is ENSC or QCLS more profitable?

Do institutionals & insiders believe in ENSC or QCLS?

Do analysts recommend ENSC or QCLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENSC vs. The Competition

Ensysce Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools